Brief: Revance Therapeutics Commenced A Plan To Exit Opul Payments Business

Revance Therapeutics

19/09/2023 14:09

Sept 19 (Reuters) - Revance Therapeutics Inc  RVNC.O :
    * REVANCE THERAPEUTICS INC: ON SEPTEMBER 17 COMMENCED A PLAN
TO
EXIT OPUL(REG) PAYMENTS BUSINESS
    * REVANCE THERAPEUTICS INC: EXIT AND RESTRUCTURING
ACTIVITIES
PREDOMINANTLY INCLUDE A REDUCTION IN OPUL(REG) PERSONNEL
HEADCOUNT
    * REVANCE THERAPEUTICS INC- INTENDS TO CONTINUE PROCESSING
PAYMENTS FOR CURRENT OPUL(REG) CUSTOMERS THROUGH JANUARY 31,
2024
    * REVANCE THERAPEUTICS INC - EXPECTS TO RECORD A
RESTRUCTURING
CHARGE IN CONNECTION WITH SUCH ACTIVITIES OF UP TO $7.0 MILLION
    * REVANCE THERAPEUTICS INC: EXPECTS TO RECORD A
RESTRUCTURING
CHARGE IN CONNECTION WITH SUCH ACTIVITIES OF UP TO $7.0 MILLION
    * REVANCE THERAPEUTICS INC- COMPANY EXPECTS TO RECORD A
RESTRUCTURING CHARGE IN CONNECTION WITH SUCH ACTIVITIES OF UP TO
$7.0 MILLION
    * REVANCE THERAPEUTICS INC: ESTIMATES TOTAL NON-CASH
IMPAIRMENT
CHARGES FROM GOODWILL AND OTHER ASSETS TO BE BETWEEN AN
ESTIMATED $80 MILLION AND $100 MILLION
    * REVANCE THERAPEUTICS- ANTICIPATES COMPLETION OF
ACTIVITIES,
INCLUDING WORKFORCE REDUCTION, RELATED CASH PAYMENTS, WILL BE
COMPLETE BY MARCH 31, 2024

Further company coverage:  RVNC.O 

 ((Reuters.Briefs@thomsonreuters.com))